Harmony Biosciences Holdings, Inc.

HRMY

$41.97

Updated: 22/09/2026, 18:11:06

Market Cap

$2.43B

Sector

Healthcare

Industry

Biotechnology

Country

Stock valuation chart

One-year closing share-price history for HRMY

Company Profile

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.

USD

NASDAQ

CEO: Jeffrey Dayno

Employees: 293

https://www.harmonybiosciences.com

Asset Summaries

Latest generated summaries for HRMY

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for HRMY.

Share price: $41.97
Market cap: $2.43B
Exchange: NASDAQ
Currency: USD
CEO: Jeffrey Dayno
Employees: 293
IPO date: 19/08/2020
Beta: 0.925
Last dividend: $0.00
Day range: $41.67 – $42.37
52-week range: $25.52 – $43.49
1-day performance: -0.31%
1-year performance: 64.45%
Current drawdown (1Y): -3.50%
CIK: 0001802665
CUSIP: 413197104
ISIN: US4131971040
Created: 07/12/2025, 04:35:27
Last update: 22/09/2026, 18:11:06

Track Harmony Biosciences Holdings, Inc. with an AI analyst

See which prediction-market events move HRMY, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to HRMY from your Railway `news_articles` table.

Harmony Biosciences Holdings, Inc. (HRMY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 09/06/2026, 13:52:40

Harmony Biosciences to Participate in Upcoming Investor Conferences

Business Wire • STOCK • 27/05/2026, 10:05:00

Harmony Biosciences Holdings, Inc. (HRMY) Q1 2026 Earnings Call Transcript

Seeking Alpha • STOCK • 07/05/2026, 20:11:15

HRMY or ARGX: Which Is the Better Value Stock Right Now?

Zacks Investment Research • STOCK • 04/05/2026, 14:40:30

Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting

Business Wire • STOCK • 16/04/2026, 10:05:00

Harmony Biosciences Holdings, Inc. (HRMY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Seeking Alpha • STOCK • 14/04/2026, 18:51:46

Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer

Business Wire • STOCK • 14/04/2026, 10:05:00

Harmony Biosciences Holdings, Inc. (HRMY) Q4 2025 Earnings Call Transcript

Seeking Alpha • STOCK • 24/02/2026, 16:37:56

3 Reasons Why Growth Investors Shouldn't Overlook Harmony Biosciences (HRMY)

Zacks Investment Research • STOCK • 16/02/2026, 14:46:06

Harmony Biosciences Chief Financial Officer Sells Shares Again After Previous Exit From Company Equity

The Motley Fool • STOCK • 01/02/2026, 03:40:33

Harmony Biosciences' CFO Sells All of Her Insider Shares, Worth $752,800

The Motley Fool • STOCK • 31/01/2026, 23:19:24